Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Pipeline Analysis

PUBLISHER: 360iResearch | PRODUCT CODE: 1573090

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1573090

COX-2 Selective NSAIDs Market by Application (Cardiology, Oncology, Pain Management), End-User (Clinics, Homecare Settings, Hospitals), Drug Type, Dosage Form - Global Forecast 2025-2030

PUBLISHED:
PAGES: 187 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (2-5 User License)
USD 4249
PDF, Excel & 1 Year Online Access (Site License)
USD 5759
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

Description

Table of Contents

List of Tables

The COX-2 Selective NSAIDs Market was valued at USD 7.83 billion in 2023, expected to reach USD 8.19 billion in 2024, and is projected to grow at a CAGR of 5.42%, to USD 11.33 billion by 2030.

COX-2 selective NSAIDs, primarily developed to reduce the gastrointestinal side effects associated with traditional NSAIDs, target the enzyme cyclooxygenase-2 (COX-2), which plays a pivotal role in inflammation and pain. The necessity for these medications arises from their ability to provide effective pain relief with a reduced risk of gastrointestinal ulcers, a common side effect of non-selective NSAIDs. They are predominantly used in managing symptoms of arthritis, acute pain, and dysmenorrhea, among others, with primary end-users being individuals suffering from chronic inflammatory conditions, healthcare providers, and hospitals. Market growth is driven by factors such as the rising prevalence of chronic inflammatory and osteoarthritic conditions, an aging population that increasingly requires pain management solutions, and ongoing research advancements aiming to enhance COX-2 inhibitors' efficacy and safety. Recent potential opportunities include the development of lower-dose formulations or combination therapies harnessing synergetic effects with other medications to further reduce adverse while improving compliance. However, the market faces challenges such as increased scrutiny over cardiovascular safety concerns linked to COX-2 inhibitors, leading to stringent regulatory constraints and limited approval for new drugs. Additionally, the availability of alternative treatments like biologics and an increased preference for natural supplements pose competitive challenges. Innovation could be directed towards developing next-generation COX-2 inhibitors with improved safety profiles, leveraging biologics for targeted therapy, and exploring personalized medicine approaches. The market is characterized by steady growth, tempered by rigorous approval processes and heavy competition, particularly from generic-drug manufacturers. Businesses should strategically invest in robust clinical trials to address safety concerns, explore partnerships for combination therapeutics, and capitalize on emerging markets with high unmet medical needs to enhance their market position and drive growth.

KEY MARKET STATISTICS
Base Year [2023] USD 7.83 billion
Estimated Year [2024] USD 8.19 billion
Forecast Year [2030] USD 11.33 billion
CAGR (%) 5.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving COX-2 Selective NSAIDs Market

The COX-2 Selective NSAIDs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic inflammatory diseases driving demand for COX-2 selective NSAIDs
    • Rising awareness among healthcare professionals about benefits of selective COX-2 inhibitors
    • Growing geriatric population leading to higher incidence of osteoarthritis and rheumatoid arthritis
    • Advancements in pharmaceutical research enhancing efficacy and reducing side effects of COX-2 inhibitors
  • Market Restraints
    • Strict advertising regulations restricting promotional activities for COX-2 selective NSAIDs
    • Public perception and awareness issues affecting market acceptance of COX-2 selective NSAIDs
  • Market Opportunities
    • Development of novel COX-2 selective NSAIDs with improved efficacy and safety profiles
    • Expansion into emerging markets with high prevalence of chronic inflammatory conditions
    • Leveraging digital marketing strategies to increase brand awareness and patient engagement
  • Market Challenges
    • Intellectual property concerns and patent expirations affecting market exclusivity for COX-2 selective NSAIDs
    • Competition from non-selective NSAIDs and their impact on market penetration of COX-2 selective NSAIDs

Porter's Five Forces: A Strategic Tool for Navigating the COX-2 Selective NSAIDs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the COX-2 Selective NSAIDs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the COX-2 Selective NSAIDs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the COX-2 Selective NSAIDs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the COX-2 Selective NSAIDs Market

A detailed market share analysis in the COX-2 Selective NSAIDs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the COX-2 Selective NSAIDs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the COX-2 Selective NSAIDs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the COX-2 Selective NSAIDs Market

A strategic analysis of the COX-2 Selective NSAIDs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the COX-2 Selective NSAIDs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkem Laboratories, Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, Dr. Reddy's Laboratories, Eli Lilly and Company, GlaxoSmithKline plc, Hikma Pharmaceuticals plc, Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the COX-2 Selective NSAIDs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Application, market is studied across Cardiology, Oncology, and Pain Management. The Cardiology is further studied across Myocardial Infarction and Stroke. The Oncology is further studied across Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer. The Pain Management is further studied across Chronic Back Pain, Osteoarthritis, Postoperative Pain, and Rheumatoid Arthritis.
  • Based on End-User, market is studied across Clinics, Homecare Settings, Hospitals, and Research Institutes.
  • Based on Drug Type, market is studied across Celecoxib, Etoricoxib, Rofecoxib, and Valdecoxib.
  • Based on Dosage Form, market is studied across Capsules, Injectables, Suspensions, and Tablets.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Show more
Product Code: MRR-5D340F440BAE

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic inflammatory diseases driving demand for COX-2 selective NSAIDs
      • 5.1.1.2. Rising awareness among healthcare professionals about benefits of selective COX-2 inhibitors
      • 5.1.1.3. Growing geriatric population leading to higher incidence of osteoarthritis and rheumatoid arthritis
      • 5.1.1.4. Advancements in pharmaceutical research enhancing efficacy and reducing side effects of COX-2 inhibitors
    • 5.1.2. Restraints
      • 5.1.2.1. Strict advertising regulations restricting promotional activities for COX-2 selective NSAIDs
      • 5.1.2.2. Public perception and awareness issues affecting market acceptance of COX-2 selective NSAIDs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel COX-2 selective NSAIDs with improved efficacy and safety profiles
      • 5.1.3.2. Expansion into emerging markets with high prevalence of chronic inflammatory conditions
      • 5.1.3.3. Leveraging digital marketing strategies to increase brand awareness and patient engagement
    • 5.1.4. Challenges
      • 5.1.4.1. Intellectual property concerns and patent expirations affecting market exclusivity for COX-2 selective NSAIDs
      • 5.1.4.2. Competition from non-selective NSAIDs and their impact on market penetration of COX-2 selective NSAIDs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. COX-2 Selective NSAIDs Market, by Application

  • 6.1. Introduction
  • 6.2. Cardiology
    • 6.2.1. Myocardial Infarction
    • 6.2.2. Stroke
  • 6.3. Oncology
    • 6.3.1. Breast Cancer
    • 6.3.2. Colorectal Cancer
    • 6.3.3. Lung Cancer
    • 6.3.4. Prostate Cancer
  • 6.4. Pain Management
    • 6.4.1. Chronic Back Pain
    • 6.4.2. Osteoarthritis
    • 6.4.3. Postoperative Pain
    • 6.4.4. Rheumatoid Arthritis

7. COX-2 Selective NSAIDs Market, by End-User

  • 7.1. Introduction
  • 7.2. Clinics
  • 7.3. Homecare Settings
  • 7.4. Hospitals
  • 7.5. Research Institutes

8. COX-2 Selective NSAIDs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Celecoxib
  • 8.3. Etoricoxib
  • 8.4. Rofecoxib
  • 8.5. Valdecoxib

9. COX-2 Selective NSAIDs Market, by Dosage Form

  • 9.1. Introduction
  • 9.2. Capsules
  • 9.3. Injectables
  • 9.4. Suspensions
  • 9.5. Tablets

10. Americas COX-2 Selective NSAIDs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific COX-2 Selective NSAIDs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa COX-2 Selective NSAIDs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkem Laboratories
  • 3. Amgen Inc.
  • 4. AstraZeneca
  • 5. Bayer AG
  • 6. Boehringer Ingelheim GmbH
  • 7. Dr. Reddy's Laboratories
  • 8. Eli Lilly and Company
  • 9. GlaxoSmithKline plc
  • 10. Hikma Pharmaceuticals plc
  • 11. Merck & Co., Inc.
  • 12. Mylan N.V.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Sanofi S.A.
  • 16. Sun Pharmaceutical Industries Ltd.
  • 17. Takeda Pharmaceutical Company Limited
  • 18. Teva Pharmaceutical Industries Ltd.
  • 19. Torrent Pharmaceuticals Ltd.
  • 20. Zydus Cadila
Show more
Product Code: MRR-5D340F440BAE

LIST OF FIGURES

  • FIGURE 1. COX-2 SELECTIVE NSAIDS MARKET RESEARCH PROCESS
  • FIGURE 2. COX-2 SELECTIVE NSAIDS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COX-2 SELECTIVE NSAIDS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. COX-2 SELECTIVE NSAIDS MARKET DYNAMICS
  • TABLE 7. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY MYOCARDIAL INFARCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STROKE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CHRONIC BACK PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY POSTOPERATIVE PAIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CELECOXIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ETORICOXIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ROFECOXIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY VALDECOXIB, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM COX-2 SELECTIVE NSAIDS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 330. COX-2 SELECTIVE NSAIDS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 331. COX-2 SELECTIVE NSAIDS MARKET, FPNV POSITIONING MATRIX, 2023
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!